期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

快速制备自体肿瘤浸润淋巴细胞联合白细胞介素2胸腔输注治疗癌性胸腔积液 被引量：2

Therapeutic effect of tumor infiltrating lymphocyte plus interleukin-2 intrapleural injection on advanced cancer patients with malignant pleural effusion
暂未订购
导出
摘要 目的:研究体外快速制备的自体肿瘤浸润淋巴细胞(TIL)联合白细胞介素2(IL-2)疗法对癌性胸腔积液的治疗作用。方法:对2003年8月至2004年11月间确诊的22例癌性胸腔积液患者,采用该作者实验室建立的胸腔积液TIL体外快速制备技术制备TIL,胸腔输注,后续胸腔内灌注IL-2,每天100万单位,连续4 d为1治疗周期,观察其疗效和不良反应。结果:采用该疗法治疗1个周期,22例患者中8例完全缓解(36.4%),11例部分缓解(50.0%),3例无效(13.6%),总有效率达86.4%。有效的病例随访中均未见治疗侧胸腔积液复发或增加;除极少数患者治疗中出现低热和胸痛外,未见有其他不良反应发生。结论:自体TIL联合IL-2治疗癌性胸腔积液,具有良好的临床应用价值。 Objective：To study the clinical effects of tumor infiltrating lymphocyte （TIL） plus interleukino2 （IL-2） intrapleural injection on malignant pleural effusion. Methods ：22 patients with malignant pleural effusion received TIL plus IL-2 therapy for one course. Results：Pleural effusion disappeared completely in 8 of 22 patients, decreased by more than 50% in volume in 11 patients. Response rate in the study was 86. 4%. Performance status improved in 19 patients. No serious side effects were observed, and no recurrence or increase of hydrothorax was observed in the follow up of CR or PR. Conclusion ：The protocol of TIL plus IL-2 described here deserved for clinical application.
作者 刘宝瑞 邹征云 钱晓萍 王燕 杜娟 胡文静 殷海涛 孔炜伟 王立峰 李丽 陈蓉
机构地区 南京大学医学院附属南京市鼓楼医院肿瘤中心
出处 《医学研究生学报》 CAS 2007年第8期833-835,共3页 Journal of Medical Postgraduates
基金 南京市医学重点科技发展基金资助项目(批准号:ZKX0112)
关键词 癌性胸腔积液 肿瘤浸润淋巴细胞 白细胞介素2 Malignant pleural effusion Tumor infiltrating lymphocyte Interleukin-2
分类号 R730.6 [医药卫生—肿瘤]
  • 相关文献

参考文献6

二级参考文献27

  • 1李志宇,薛华,何生,黎介寿.葡萄球菌肠毒素A脂质体诱导人肝癌肿瘤浸润淋巴细胞分泌细胞因子的实验研究[J].医学研究生学报,2004,17(12):1076-1078. 被引量：4
  • 2李彪如,童善庆,朱佑明,胡宝瑜,张希衡,陆静,吴建和,胡洪亮,沈鼎鸿,陆德源.一种高活力分离肿瘤浸润淋巴细胞方法的建立[J].免疫学杂志,1994,10(1):44-47. 被引量：24
  • 3[1]Rosenberg SA. Adoptive immunotherapy for cancer. Scientific American, 1990, (5): 62.
  • 4[2]Inoue Y. Induction of killer cells from lymphcytes in pleural effusion of advanced lung cancer patients. Jpn J Cancer Res,1990, 81: 1012.
  • 5[3]Brouwenstijn N. Renal -cell carcinoma- specific lysis by cytotoxic T lymphocyte clones isolated from peripheral blood lymphocytes and tumor infiltrating lymphocytes. Int J Cancer,1996, 68: 2177.
  • 6[4]Van den Hove LE. Identification of an enriched CD4+ CD8 alpha+ + CD8 beta+ T - cell subset among tumor - infiltrating lymphocytes in human renal cell carcinoma. Int J Cancer, 1997,71: 2, 178.
  • 7崔祥--，实用肺脏病学，1991年
  • 8陈丙莺，上海免疫学杂志，1989年，9卷，218页
  • 9Dudley M E, Wunderlich J R, Robbins P F, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes[J]. Science, 2002,298 (5594): 850-854.
  • 10Kan N. Analysis of 5-year survival among breast cancer patients with malignant pleural effusion receiving intrapleural OK-432 followed by adoptive transfer with cultured effusion lymphocytes[J]. Gan To Kagaku Ryoho, 2003,30(11): 1559-1561.

共引文献25

同被引文献20

  • 1周志毅,石群立,王修来.原发性中枢神经系统淋巴瘤遗传学及发病机制研究进展[J].医学研究生学报,2007,20(4):438-441. 被引量：8
  • 2Gerstner E, Batchelor T. Primary CNS lymphoma[ J ]. Expert Rev Anticancer Ther, 2007, 7 (5) : 689-700.
  • 3Zou W. Immunosuppressive networks in the tumor environment and their therapeutic relevance [ J]. Nat Rev Cancer, 2005, 5 ( 4 ) : 263-274.
  • 4Lotze MT, Chang AE, Seipp CA, et al. High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer. Rosponses, treatment-related morbidity, and histologic findings[J]. JAMA,1986, 256(22): 3117-3124.
  • 5Muul LM, Spiess PJ, Director EP, et al. Identification of specific cytolytic immune response against tumor in humans bearing malignant melanoma[ J]. J Immunol, 1987, 138 (3) : 989-995.
  • 6Smyth M J, Godfrey DI, Trapani JA. A fresh look at tumor immunosurveillance and immunotherapy [ J ]. Nat Immunol, 2001 , 2 (4) :293-299.
  • 7Ansell SM, Stenson M, Habermann TM, et al. CD4 + T-cell immune response to large B-cell non-Hodgkin' s lymphomas predicts patient outcome [J]. J Clin Oncol, 2001, 19 (3) : 720- 726.
  • 8Dave S, Wright G, Tan B, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells[J]. N Engl J Med, 2004, 351(21) : 2159-2169.
  • 9Bashir R, Chamberlain M, Ruby E, et al. T-cell infiltration of primary CNS lymphoma [ J ]. Neurology, 1996, 46 ( 2 ) : 440- 444.
  • 10Riemersma SA, Oudejans JJ, Vonk MJ, et al. High numbers of tumour-infihrating activated cytotoxic T lymphocytes, and frequent loss of HLA class Ⅰ and Ⅱ expression, are features of aggressive B cell lymphomas of the brain and testis[ J]. J Pathol, 2005, 206(3) : 328-336.

引证文献2

二级引证文献5

医学研究生学报
2007年 第8期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部